ClinicalTrials.gg
RecruitingNCT05078957FRAMIVIHUpdated Sep 25, 2025

Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV

An observational study in HIV Infections, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Hôpital Européen Marseille · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
132
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Planned enrollment
36th of 59
132 · median 200
Started
2023
with 8 others
Observational
59 of 278
13 open now
Primary completion
2030-03
later than 25 of 26 live
Registered
243rd of 278
by date

Among the 278 studies in HIV Infections with a site in France, this one is the 36th largest by planned enrollment of the 59 observational ones that give a count, is one of 9 that started in 2023, is one of 59 observational ones, reaches primary completion later than 25 of the 26 other live ones, and was the 243rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

Analysis of gut microbiota becomes more and more accessible in recent years. Experimental data in both animal and human studies have demonstrated that imbalance of the gut microbiota which is called symbiosis may participate in an accelerated procedure of ageing as well as the expression of frailty phenotype. People living with HIV (PLHIV) present markers of phenotypic frailty on average 10 years before uninfected people.

In this population structural and functional modifications of GALT (Gut Associated Lymphoid Tissue) are observed early after HIV infection and persist despite virological suppression on ART (AntiRetroviral Treatment). These GALT modifications are associated with microbial translocation that is also correlated with immune activation and dysbiosis.

The objective of study is to explore gut microbiota of PLWH over 5 years, as well as to study associations of its longitudinal evolution with frailty markers and burden of comorbidities.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People Living with HIV (PLWH)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals infected with in the stable phase of their disease (absence of disease outbreak and absence of therapeutic modification within 3 months before inclusion),
  • Subject with ongoing HIV follow-up on an outpatient basis (outpatient or day hospital consultation) in the participating center, and having virological suppression at the threshold of 50 copies / mL for at least 5 years (tolerance of blips \< 200 copies / mL during this period)
  • Aged ≥ 55 at baseline
  • CD4 + T cell nadir> 200 / mm3
  • Giving free and informed written consent
  • Being affiliated with or benefiting from a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.
  • Subject not followed regularly in the participating center,
  • Subject only coming for full hospitalization
  • Subject in the primary infection phase of less than 1 year
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
132 participants (estimated)
Patient registry
No

Groups and cohorts

  • Frail PLWH

    Other: Stool sampling · Other: Frailty phenotype · Other: Blood plasma collection

  • Pre frail PLWH

    Other: Stool sampling · Other: Frailty phenotype · Other: Blood plasma collection

  • No frail PLWH

    Other: Stool sampling · Other: Frailty phenotype · Other: Blood plasma collection

Interventions

  • OtherStool sampling

    Stool samples will be collected from participants at baseline and annually during 5 years

  • OtherFrailty phenotype

    According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.

  • OtherBlood plasma collection

    Blood plasma collection to measure persistent inflammation and immune activation

06

What researchers measure

Primary outcomes

  1. Variation of the Shannon index between 0 and 5 years in different groups of PLWH

    Time frame: Five years

Secondary outcomes

  1. Variation of the Shannon index between 0 and 3 years in different groups of PLWH (frail, pre frail, not frail)

    Time frame: Three years

  2. Assaying inflammation markers(CRP, IL-6, sCD14, sCD163, TNFa, IP10, I-FABP, LBP, D-dimers, K/T ratio) annually and for 5 years in different groups of PLWH

    Time frame: Five years

  3. Correlation between the Shannon index and the number of comorbidities associated with 0, 3 and 5 years in the different groups of PLWH

    Time frame: Five years

07

Study locations

1 of 1 sites recruiting
  • Hôpital Européen Marseille
    Marseille, 13003, France
    Recruiting
    • Myriam BENNANI · Contact
    • Christina PSOMAS, Dr · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2030, 75 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 75 months is above that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Oct 15, 2021
StartActual
Dec 5, 2023
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2030
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05078957
Lead sponsor
Hôpital Européen Marseille
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
Dec 5, 2023
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Sep 25, 2025

Study contacts

Myriam BENNANI
Contact
m.bennani@hopital-europeen.fr
0413428351

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion